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The impact of Medicare prescription drug
coverage on the use of antidementia drugs
Nicole R Fowler1*†, Yi-Fan Chen2†, Christiana A Thurton3, Aiju Men4, Eric G Rodriguez1 and Julie M Donohue4*†
Abstract
Background: Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although
the efficacy of these drugs has been demonstrated, their effectiveness, from the perspective of patients and
caregivers, has been questioned. Little is known about whether the demand for cholinesterase inhibitors and
memantine are sensitive to out-of-pocket cost. Using the 2006 implementation of Medicare Part D as a natural
experiment, this study examines the impact of changes in drug coverage on use of cholinesterase inhibitors and
memantine by comparing use before and after Medicare Part D implementation among older adults who did and
did not experience a change in coverage.
Methods: Retrospective analyses of claims data from 35,102 community-dwelling Medicare beneficiaries in Pennsylvania
aged 65 or older. Beneficiaries were continuously enrolled in a Medicare Advantage plan from 2004 to 2007. Outcome
variables were any use of donepezil (AriceptW), galantamine (RazadyneW), rivastigmine (ExelonW), tacrine (CognexW), or
memantine (NamendaW) each year and the number of 30-day prescriptions filled for these drugs. Independent variables
included type of drug benefit pre–Part D (No coverage, $150 cap, $350 cap, and No cap as the reference group), time
period, and their interaction. Sensitivity analyses were conducted to test if there are differences in use by drug class or if
beneficiaries with a diagnosis of dementia pre–Part D experienced an increase in use post–Part D.
Results: The No coverage group had a 38% increase in the odds ratio of any use of antidementia medications (P= 0.0008)
post–Part D relative to the No cap group. All four coverage groups had significant increases in number of 30-day
prescriptions (P< 0.001) over the study period. In adjusted models that included the sub-sample with any use pre–Part D,
the No coverage group had a 36% increase in prescriptions (P = 0.002) and the $350 cap group had a 15%
increase (P = 0.003) after adjusting for trends in the No cap group. Results from the sensitivity analysis for the
sub-sample with a diagnosis of dementia pre–Part D show that each group had significant increases in 30-day
prescriptions compared to the No cap control group (P < 0.05).
Conclusions: Use of cholinesterase inhibitors and memantine in our sample increased and a greater increase in use
was observed among Medicare beneficiaries who experienced improvements in drug coverage under Medicare Part D.
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Background
Dementia is a prevalent condition, affecting an estimated
5.4 million people, including 1 of every 8 adults 65 years or
older [1]. The estimated societal costs of dementia include
health care spending and lost productivity of caregivers is
approximately US$200 billion [2]. Two classes of medica-
tion – cholinesterase inhibitors (donepezil, galantamine,
rivastigmine, and tacrine) and a neuropeptide-modifying
agent (memantine) – introduced to treat dementia have
reached sales in excess of $1 billion. In 2008, it was esti-
mated that 24.7% of older adults with dementia living in
the community were taking a cholinesterase inhibitor or
memantine (hereafter referred to antidementia drugs) [3,4],
at an average out-of-pocket cost of US $166 [5].
There is considerable controversy over the value of
antidementia medications as they are currently used.
These agents slow the progression of cognitive decline
but do not reverse the effects of the disease [6,7]. Ran-
domized controlled trials of cholinesterase inhibitors have
shown short–term positive effects on cognitive perform-
ance in patients with mild Alzheimer’s disease [8]. There
is little evidence to support their use in patients with
advanced disease [3,9], yet studies show that as much as
10-30% of use of these medications is among people
with severe dementia living in nursing homes [10,11].
Furthermore, these drugs are primarily recommended for
Alzheimer’s-type dementia, where the strongest evidence of
efficacy has been found [7]. Finally, widespread use of these
drugs has been questioned due a lack of evidence that they
improve outcomes that are meaningful to patients and
caregivers such as the rate of decline in activities of daily
living and behavioral symptoms [7,12,13]. Perhaps as a re-
sult of this mixed evidence, prescribing guidelines for these
medications are inconsistent [14-17], even for patients with
mild cognitive impairment who may stand to benefit more
than patients with severe impairment [18,19].
Population based rates of use for antidementia drugs
vary, as do estimates of persistence of therapy overtime.
Some studies have found that as many as 50% of people
who initiate use of an antidementia medication discontinue
use within 1 year [20]. Little is known about the effect of
out-of-pocket costs on use of antidementia medications.
This gap in knowledge is important given the significant
expansion in drug coverage brought about by Medicare
Part D, which was implemented in 2006 and covers drugs
for 27 million beneficiaries. Previous studies have found
Part D to increase both appropriate and inappropriate use
of medications [21-24].
The objective of this study was to determine the
effect of insurance coverage on the use of antidementia
medications. This study had two hypotheses: first, that the
overall proportion of patients using these drugs would
increase over the study period; second, that the
increase in use of these drugs would be higher
among patients gaining prescription drug coverage
under Part D.
Methods
Study sample
With approval from the University of Pittsburgh Institu-
tional Review Board, we obtained and examined the
pharmacy, inpatient and outpatient medical claims, and
enrollment records of patients covered by a large health
insurer in Pennsylvania from 2004–2007. The criteria
for inclusion in the retrospective cohort study were
community-dwelling Medicare beneficiaries who were
65 years or older and were alive and continuously en-
rolled from 2004 to 2007 in one of the Medicare man-
aged care plans (Medicare Advantage) offered by the
health insurer. The sample was limited to individuals
who filled at least one prescription for any drug in one
of several thousand pharmacies in the insurer’s network
to ensure inclusion of fills even for those with no drug
benefits pre–Part D. All enrollees in the plan, regardless
of the level of coverage, had an incentive to present their
insurance card at these pharmacies because they re-
ceived a 15% discount. We are therefore confident that
we observed prescription fills for these enrollees.
The strength of the data, compared to national Medi-
care data, is the availability of pre–Part D drug utilization
and drug benefits as a way to compare use pre and post–
Part D. Patients were categorized into 4 groups based on
their pre–Part D drug coverage: those who had no drug
coverage (No coverage group); those who had quarterly
drug benefit limits on what the plan would pay of either
$150 ($150 cap group) or $350 ($350 cap group), based
solely on their county of residence; and those who were
enrolled in employer or union group plans through the
same insurer that offered supplemental drug coverage
with no quarterly cap (No cap group). The $150 cap and
$350 cap groups had copayments of $12 and $20 for gen-
eric and brand name drugs, respectively. The No cap
group had copayments of $10 and $20, respectively. Other
medical benefits, such as outpatient visit copayments,
were similar for the 4 groups.
The implementation of Medicare Part D in January
2006 was used a natural experiment to examine the im-
pact of changes in drug coverage on use of antidementia
drugs. Use of these drugs was compared before and after
this date in both the full study sample and among a sub-
sample who had any use of an antidementia drug pre–Part
D. When Part D went into effect, beneficiaries in the No
coverage group and those in the $150 cap and $350 cap
groups automatically received the plan’s Part D benefit.
The coverage, like that of most Medicare Advantage pre-
scription drug plans, did not include a deductible.
Beneficiaries had copayments on drugs until their total
drug spending for the year reached the “donut hole” (the
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coverage gap for out-of-pocket payments from $2,250 to
$5,100 in 2006 dollars). In the donut hole, the plan either
covered no drugs or covered only generic drugs with an $8
or $10 copayment. In 2006, no antidementia drugs were
generic, so beneficiaries with Part D coverage would have
had to pay 100% of the costs of these drugs once they
reached the donut hole. Beneficiaries in the No cap group
had stable drug benefits throughout the study period and
were not exposed to coverage limits and served as the com-
parison group. This comparison group accounts for secular
trends in use of these drugs among beneficiaries enrolled
with the same insurance company who did not experience a
change in their drug benefit as a result of Medicare Part D.
Outcomes measures, variables, and covariates
This study had two outcome measures: a population-
based measure of any use of the 5 antidementia drugs
approved by the Food and Drug Administration for the
treatment of dementia: donepezil (AriceptW), galantamine
(RazadyneW), rivastigmine (ExelonW), tacrine (CognexW),
or memantine (NamendaW); and a measure of the annual
number of 30-day prescriptions filled for any of these
medications conditional on any use pre–Part D.
Our primary independent variables were the type of drug
benefit pre–Part D (No coverage, $150 cap, $350 cap, and
No cap as the reference group), time period, and their
interaction. Our covariates included the following: sex; age;
census-block group-level data on race, proportion with
incomes below the poverty line, urban residence; and three
measures of health status. First, we included indicators for
certain chronic conditions (binary variables for congestive
heart failure, depression, diabetes, hypertension, and ische-
mic heart disease). Second, we included a time–varying
prospective risk score, a proxy for health status. The risk
scores were calculated at the end of each year with Risk
Grouper (DxCG, Boston, MA), a software program that
uses a series of proprietary algorithms based on the pres-
ence of dozens of ICD-9 diagnostic codes and Healthcare
Common Procedure Coding System (HCPCS) codes. The
scores are similar to the hierarchical condition category
weights that are used by the Centers for Medicare and
Medicaid Services to adjust Medicare Advantage Part D
payments. A higher score indicates the likelihood of greater
spending in the following year. Third, we included mea-
sures of the use of medical services (number of outpatient
physician visits each year and outpatient costs).
Statistical analyses
Descriptive statistics were used to characterize the study
sample. To compare the characteristics of the 4 study
groups, chi-square tests were used for categorical var-
iables and t tests and multivariate analysis of variance
(MANOVA) for continuous variables. To test the difference
of two dependent proportions, McNemar’s test was used.
A generalized estimating equation (GEE) [25] with a bi-
nomial distribution, logit link function, and exchangeable
correlation structure was fitted to model any use of
antidementia drugs annually, as a group and by drug class.
Similar models were fitted for the number of prescriptions
annually, except using negative binominal distribution,
and log link function. The negative binominal distribution
dealt with the issue of over dispersion of the count, and
the correlation structure took into account the depend-
ency within patients. By putting the interaction terms of
time period and the drug benefit group in the model, we
were able to explore the net effects of the implementation
of Part D within each coverage group adjusting for the co-
variates. This is achieved by comparing the adjusted odds
ratio of the No coverage group, $150 cap group, and $350
cap group with that of the reference group (No cap group)
to adjust for secular trends in the use of antidementia
medications unrelated to Part D’s implementation.
Additionally, a sensitivity analysis was conducted using
only the sub-sample of beneficiaries who had an ICD-9
diagnosis code for any type of dementia (e.g., Alzheimer’s
disease, vascular dementia, senility, etc.) pre–Part D and
compared use of antidementia drugs pre and post–Part D,
by coverage group.
SAS version 9.2 (SAS Institute, Inc., Cary, NC) was used
all analyses with the supplement of Excel 2007 for plots.
Any P value of <0.05 was considered to be statistically
significant.
Results
The total study sample consisted of 35,102 patients. Of
these 11.2% (n = 3,939) were in the No coverage group,
7.5% (n = 2,662) in the $150 cap group, 54.2% (n = 19,014)
in the $350 cap group, and 27.0% (n = 9,487) in the No cap
group (Table 1). In each group, there were more beneficiar-
ies who were women (≥52.5%), aged 65–74 years (≥47.4%),
and white (≥0.92), and with a median income above
$34,000. Compared to the No cap group, the other three
groups had a higher proportion of females (P ≤ 0.002), were
more likely to be older than 75 years of age (P ≤ 0.001),
and were more likely to be >200% below the poverty
line (P ≤ 0.001), which reflects that these groups were less
likely to have coverage through a former employer. The
No coverage group had lower percentages of patients
with comorbidities and lower outpatient visits and
costs. However, these four groups had similar risk
scores over time indicating comparable health status.
None of the beneficiaries, in any group, had a claim
for tacrine (CognexW) during the study period. This is
not surprising given its known side effects of high
toxicity of enzymes in the liver [26]. Only beneficiar-
ies in the $350 cap group and No cap group had
claims for galantamine (RazadyneW) in the pre–Medicare
Part D period.
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Table 1 Characteristics of the study sample in 2005 (n = 35,102)
Pharmacy benefit group
No coverage (n = 3,939) $150 cap (n = 2,662) $350 cap (n = 19,014) No cap (n = 9,487)
Female sex, No. (%) 2,183 (55.42)* 1,658 (62.28)* 11,806 (62.09)* 4,984 (52.54)
Age, y, No. (%)
65-74 1,866 (47.37)* 1,323 (49.70)* 9,983 (52.50)* 5,755 (60.66)
75-84 1,746 (44.33)* 1,080 (40.57)* 7,478 (39.33)* 3,232 (34.07)
≥85 327 (8.30)* 259 (9.73)* 1,553 (8.17)* 500 (5.27)
Race, mean (SE)
White 0.930 (0.002)* 0.960 (0.001)* 0.919 (0.001)* 0.921 (0.001)
African American 0.052 (0.002)* 0.024 (0.001)* 0.060 (0.001)* 0.057 (0.001)
Status below poverty line, mean (SE)
<100% 0.106 (0.001)* 0.111 (0.001)* 0.101 (0.000)* 0.099 (0.001)
100-200% 0.183 (0.001)* 0.209 (0.001)* 0.172 (0.000)* 0.169 (0.001)
>200% 0.712 (0.002)* 0.680 (0.002)* 0.727 (0.001)* 0.732 (0.001)
Urban residence, mean (SE) 0.737 (0.005)* 0.577 (0.007)* 0.791 (0.002) 0.797 (0.003)
Income, US dollars, median (SE) 37,573.77 (159.01)* 34,839.85 (111.25)* 38,957.08 (78.64)* 39,501.05 (110.80)
Comorbidity, No. (%)
Congestive heart failure 507 (12.87) 381 (14.31) 2,656 (13.97)* 1,240 (13.07)
Depression 259 (6.58)* 215 (8.08) 1,465 (7.71) 725 (7.64)
Diabetes 905 (22.98)* 679 (25.51) 4,755 (25.01) 2,464 (25.97)
Hypertension 2,554 (64.84)* 1,892 (71.07) 1,3640 (71.74)* 6,649 (70.09)
Ischemic heart disease 1,110 (28.18) 757 (28.44) 5,551 (29.20) 2,796 (29.47)
Prospective risk score, mean (SE)
2004 0.825 (0.011) 0.855 (0.014) 0.859 (0.005) 0.844 (0.008)
2005 0.919 (0.012) 0.950 (0.016) 0.942 (0.006) 0.924 (0.009)
2006 1.034 (0.015) 1.040 (0.017) 1.044 (0.007) 1.029 (0.010)
2007 1.153 (0.017) 1.186 (0.020)* 1.176 (0.008)* 1.141 (0.011)
Use of medical services in 2005, mean (SE)
Outpatient visits, No. 23.146 (0.407)* 25.158 (0.585) 25.134 (0.193)* 25.876 (0.287)
Outpatient costs, US dollars 3,498.249 (92.900)* 3,532.557 (124.010)* 3,741.035 (47.238) 3,869.198 (65.966)
Medical costs, US dollars 6,000.270 (186.796) 5,837.965 (226.731) 6,208.844 (87.559) 6,266.855 (130.414)
Prescriptions of antidementia drugs, mean (SE)
2004-2007
AriceptW 0.675 (0.064)* 0.841 (0.090) 0.878 (0.036) 0.908 (0.054)
RazadyneW 0 0 0.008 (0.002) 0.019 (0.005)
ExelonW 0.079 (0.023)* 0.085 (0.032)* 0.100 (0.012)* 0.228 (0.031)
CognexW 0 0 0 0
NamendaW 0.476 (0.055) 0.343 (0.054)* 0.401 (0.023)* 0.498 (0.038)
Pre–Part D
AriceptW 0.172 (0.026)* 0.262 (0.039) 0.297 (0.016) 0.335 (0.025)
RazadyneW 0 0 0.008 (0.002) 0.019 (0.005)
ExelonW 0.032 (0.013)* 0.044 (0.018)* 0.040 (0.006)* 0.106 (0.016)
CognexW 0 0 0 0
NamendaW 0.102 (0.018) 0.084 (0.019)* 0.096 (0.008)* 0.140 (0.015)
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Among the full sample, the proportion of individuals
using antidementia drugs increased from 2.4% in 2004
to 5.3% in 2007. During the entire study period, the No
coverage group experienced the largest growth in use,
with proportions increasing from 1.9% in 2004 to 2.2%
in 2005, and to 3.5% in 2006, and 5.3% in 2007. Rates of
use post–Part D (2006 and 2007) were significantly dif-
ferent in 2004 (P ≤ 0.001) but not in 2005 (P = 0.06)
(Figure 1). Table 2 displays the pre–post comparison of
any use within each coverage group as well as the ad-
justed odds ratios (AOR) comparing increases in use in
the No coverage, $150 and $350 cap groups relative to the
No cap comparison group. Each coverage group experi-
enced a statistically significant (P < 0.001) increase in the
likelihood of antidementia medication use. The magnitude
of the increase in odds ratio of use in the No coverage
group (AOR = 2.19, 95% [CI], 1.85-2.59) was 38.0% greater
than in the No cap group (AOR = 1.59, 95% [CI], 1.47-1.72)
whose coverage was stable during the period. The groups
with limited coverage pre– Part D ($150 and $350 caps)
experienced similar increases in any use to the No cap
group that were not significantly different.
Among the full sample, 3.4% of beneficiaries (n = 1,197)
had at least one 30–day antidementia drug prescription
pre–Part D. Conditional on any use before Part D, the
mean number of 30–day prescriptions filled for these
drugs was 6.82 in the pre–Part D period and 9.95 in the
post–Part D period across all coverage groups Among
those with use pre–Part D, the mean number of 30–day
prescriptions of antidementia drugs increased over time
from 5.80 to 10.30 in the No coverage group, 5.91 to 8.99
in the $150 cap group, 6.29 to 9.47 in the $350 cap group,
and 8.42 to 11.04 in the No cap group.
The adjusted odds ratio of antidementia prescriptions
filled post–Part D vs. pre–Part D were statistically sig-
nificant in all groups (P <0.001). In multivariable models
that used the No cap group as the reference group and
adjusted for covariates, the No coverage group had a
36% greater increase in prescriptions filled (AOR, 1.36;
95% confidence interval [CI], 1.12-1.65; P = 0.002), and
the $350 cap group had a 15% greater increase (AOR,
1.15; 95% [CI], 1.05-1.27; P = 0.003). The increase for the
$150 cap group was not statistically significantly different
than that for the No cap group (P = 0.118) (Table 3).
The adjusted odds ratios of the number of cholinester-
ase inhibitor prescriptions filled post–Part D vs. pre–Part
D were statistically significant in all groups (P <0.05). In
multivariable models that used the No cap group as the
comparison group and adjusted for covariates, the No
coverage group had 28% greater increase in number of
prescriptions filled (AOR, 1.28; 95% confidence interval
[CI], 1.02-1.61; P = 0.03), and the $350 cap group had a
15% greater increase (AOR, 1.15; 95% CI, 1.05-1.27; P =
0.004), relative to the No cap group. The increase for the
$150 cap group was not statistically significantly different
than that for the No cap group (P = 0.141) (Table 4).
The adjusted odd ratios of number of memantine pre-
scriptions filled post–Part D vs. pre–Part D were statisti-
cally significant in all groups (P <0.0001). In multivariable
models that used the No cap group as the reference group
and adjusted for covariates, the No coverage group saw a
statistically significant increase post–Part D relative to the
No cap group (Table 4).
Results from the sensitivity analysis, that was limited to
the sub-sample of beneficiaries with a diagnosis of demen-
tia pre–Part D (n = 3,088), yielded similar results. The ad-
justed ratios of cholinesterase inhibitor prescriptions filled
post–Part D vs. pre–Part D showed statistically significant
Table 1 Characteristics of the study sample in 2005 (n = 35,102) (Continued)
Post–Part D
AriceptW 0.503 (0.046) 0.579 (0.059) 0.581 (0.023) 0.573 (0.033)
RazadyneW 0 0 0 0
ExelonW 0.047 (0.013)* 0.041 (0.016)* 0.060 (0.007)* 0.122 (0.017)
CognexW 0 0 0 0
NamendaW 0.375 (0.041) 0.259 (0.040)* 0.305 (0.017) 0.357 (0.026)
Abbreviations: SE, standard error.
*differences are statistically significant at p < 0.05 level compared to the No cap group.
Figure 1 Trends in the proportion of antidementia drug use in
the study sample of 35,102 patients, categorized based on
drug coverage.
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increase in all coverage groups (P <0.0001). In multivari-
able models that used the No cap group as the reference
group and adjusted for covariates, the No coverage group
had a 80% greater increase in prescriptions filled than the
No cap group (adjusted ratio, 1.80; 95% confidence inter-
val [CI], 1.42-2.27; P < 0.0001), the $150 cap group had a
29% greater increase in prescriptions filled (AOR, 1.29;
95% confidence interval [CI], 1.02-1.63; P < 0.05), and the
$350 cap group had a 22% greater increase (AOR, 1.22;
95% CI, 1.09-1.36; P = 0.0004) (Table 5).
Discussion and conclusions
The growing prevalence of dementia and the significant
emotional and economic toll of the condition on patients
and families will likely increase the demand for, and spend-
ing on, antidementia medications. Our study found sub-
stantial increases in the proportion of older Medicare
beneficiaries who used these drugs during the study period
(2004–2007) and in the number of 30-day prescriptions for
these drugs among existing users. Given that the increase
in use was greatest among those experiencing the most sig-
nificant change in drug coverage after Part D’s implementa-
tion; the demand for antidementia medications appears to
be responsive to changes in out-of-pocket cost. The
devastating effects of dementia on patients and families
may promote a demand for these medications both in
patients who do and do not stand to benefit, particularly
when insurance coverage results in low out-of-pocket costs.
Previous studies have shown that Part D has had an
impact on the use of drugs with a strong evidence base and
clear guidelines recommending their use [21,23,24,27] as
well as for drugs without a strong evidence base [21]. We
find that the magnitude of the increase in use of
antidementia medications associated with Part D is similar
to that found for lipid-lowering and antidiabetic medica-
tions [27], as well as for drugs to treat heart failure [22] and
depression [23].
Medicare Part D plans have several tools at their disposal
to improve the appropriateness of prescription drug use
among older adults including tiered payment structures for
drugs with reduced cost sharing for generic drugs and
higher co-payments for brand names drugs, or for drugs
with little evidence of effectiveness in some populations. In
2008, donepezil (AriceptW) was available only as a brand
name drug and was the seventh most commonly dispensed
brand-name drug and the ninth most expensive drug used
by Medicare beneficiaries [28]. More than one-third of
national Medicare Part D plans had donepezil (AriceptW)
Table 2 Impact of Medicare Part D on antidementia prescriptions filled annually
Pharmacy benefit
group
Proportion with any
use pre–Part D
Proportion with any
use post–Part D
Adjusted odds ratio* of
pre–Part D vs. post–Part
D drug use
Comparison of the adjusted odds
ratio* of the no coverage, $150 cap,
and $350 cap groups with that of
the no cap group
AOR (95% CI) P Value AOR (95% CI) P Value
No coverage group 0.02 (0.14) 0.04 (0.20) 2.19 (1.85-2.59) <0.0001 1.38 (1.14-1.66) 0.0008
$150 cap group 0.03 (0.16) 0.05 (0.21) 1.80 (1.52-2.13) <0.0001 1.13 (0.94-1.37) 0.1939
$350 cap group 0.03 (0.16) 0.05 (0.21) 1.71 (1.61-1.82) <0.0001 1.07 (0.97-1.19) 0.1626
No cap group 0.03 (0.17) 0.05 (0.21) 1.59 (1.47-1.72) <0.0001 [Reference]
Abbreviations: AOR, adjusted odds ratio CI, confidence interval; SD, standard deviation.
* Analyses were adjusted for sex; age; census-block group-level data concerning race, status below poverty line, residence; health status data (binary variables for
congestive heart failure, depression, diabetes, hypertension, and ischemic heart disease); and prospective risk score.
Table 3 Impact of Medicare Part D on antidementia prescriptions filled annually among beneficiaries with any
antidementia drug use pre-part D (n = 1,197)
Pharmacy benefit
group
Mean No. (SD) of pre–Part
D prescriptions
Mean No. (SD) of post–Part
D prescriptions
Adjusted odds ratio* of
pre–Part D vs. post–Part
D prescriptions
Comparison of the adjusted odds
ratio* of the no-coverage, $150-cap,
and $350-cap groups with that of
the no-cap group
AOR (95% CI) P Value AOR (95% CI) P Value
No coverage
group
5.80 (6.26) 10.30 (8.56) 1.76 (1.47-2.10) <0.0001 1.36 (1.12-1.65) 0.0018
$150 cap group 5.91 (5.85) 8.99 (7.35) 1.51 (1.27-1.80) <0.0001 1.16 (0.96-1.41) 0.1177
$350 cap group 6.29 (5.99) 9.47 (7.92) 1.49 (1.41-1.58) <0.0001 1.15 (1.05-1.27) 0.0031
No cap group 8.42 (7.07) 11.04 (8.19) 1.30 (1.20-1.40) <0.0001 [Reference]
Abbreviations: AOR, adjusted odds ratio CI, confidence interval; SD, standard deviation.
* Analyses were adjusted for sex; age; census-block group-level data concerning race, status below poverty line, residence; health status data (binary variables for
congestive heart failure, depression, diabetes, hypertension, and ischemic heart disease); and prospective risk score.
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on their formularies with no utilization management
restrictions, yet, 7 of 47 plans required prior authorization
before coverage, while 26 plans had limits on quantity [28].
Little is known about the effects of these utilization man-
agement tools on overall use, or on targeting use to those
most likely to benefit (e.g., those in early stages of
the disease).
Our study had several limitations that deserve mention.
First, our study sample consisted of community-dwelling
older adults who were living in western Pennsylvania who
were enrolled with a single insurer and thus may not be
representative of Medicare beneficiaries nationally. Second,
it is possible that we did not observe in the claims data all
prescriptions filled for those with limited or no coverage be-
fore Part D, however, censoring was likely mitigated by lim-
iting the sample to claims data of individuals who filled at
least 1 prescription in the insurer’s network of pharmacies.
Third, prescription fills may overestimate actual medical
use but we do not expect this to vary by coverage group or
over time in a way that would bias our estimate. Fourth, we
chose to select the sample for our primary analysis based
on use of antidementia drugs pre–Part D rather than on
the presence of a diagnosis code for dementia, as in the
sensitivity analysis. This choice was made based on results
from previous work about the inconsistency and
underreporting of dementia in claims data [29,30] and due
to the fact that use of these drugs for anything other than
memory or cognitive complaints in older adults is minimal.
Nevertheless it is possible that beneficiaries who use one of
these five drugs may be using it for a condition such as
Parkinson’s disease. In addition, we were unable to measure
or control for the severity of dementia using insurance
Table 4 Impact of Medicare Part D on antidementia prescriptions filled annually among beneficiaries with any
antidementia drug use pre-part D (n = 1,197) by drug category
Pharmacy benefit
group
Mean No. (SD) of
pre–part
d prescriptions
Mean No. (SD) of
post–part
d prescriptions
Adjusted ratio* of pre–part
D vs. Post–part d prescriptions
Comparison of the adjusted
ratio* of the no-coverage, $150-cap,
and $350-cap groups with that
of the no-cap group
Ratio (95% CI) P Value Ratio (95% CI) P Value
Cholinesterase inhibitors
No coverage group╪ 3.87 (4.53) 5.44 (5.33) 1.40 (1.13-1.73) 0.0022 1.28 (1.02-1.61) 0.0323
$150 cap group╪ 4.64 (4.71) 5.90 (5.27) 1.27 (1.05-1.53) 0.0125 1.16 (0.95-1.42) 0.1410
$350 cap group** 4.92 (4.68) 6.24 (5.32) 1.26 (1.18-1.34) <0.0001 1.15 (1.05-1.27) 0.0040
No cap group** 6.45 (5.27) 7.09 (5.59) 1.09 (1.01-1.18) 0.0280 [Reference]
NamendaW
No coverage group 1.92 (3.57) 4.86 (5.46) 2.50 (1.98-3.16) <0.0001 1.26 (0.97-1.66) 0.0884
$150 cap group 1.27 (2.87) 3.09 (4.73) 2.38 (1.74-3.25) <0.0001 1.20 (0.85-1.69) 0.2959
$350 cap group 1.37 (3.05) 3.24 (4.88) 2.33 (2.06-2.64) <0.0001 1.18 (098.-1.41) 0.0816
No cap group 1.97 (3.74) 3.95 (5.15) 1.98 (1.73-2.27) <0.0001 [Reference]
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; SD, standard deviation.
* Analyses were adjusted for sex; age; census-block group-level data concerning race, status below poverty line, residence; health status data (binary variables for
congestive heart failure, depression, diabetes, hypertension, and ischemic heart disease); and prospective risk score.
╪ AriceptW andExelonW.
** AriceptW, Razadyne, and ExelonW.
Table 5 Impact of medicare part d on antidementia prescriptions filled annually among beneficiaries with a dementia
diagnosis pre-part D (n = 3,088)
Group based on
coverage of
drugs in the
insurance plan
Mean No. (SD)
of pre–Part
D prescriptions
Mean No. (SD)
of post–Part
D prescriptions
Adjusted odds ratio* of pre–Part
D vs. post–Part D prescriptions
Comparison of the adjusted odds
ratio* of the no-coverage, $150-cap,
and $350-cap groups with that
of the no-cap group
AOR (95% CI) P Value AOR (95% CI) P Value
No-coverage group 1.61 (4.26) 3.88 (7.04) 2.47 (1.99-3.07) <0.0001 1.80 (1.42-2.27) <0.0001
$150-cap group 1.75 (4.20) 3.08 (5.99) 1.77 (1.42-2.20) <0.0001 1.29 (1.02-1.63) 0.0341
$350-cap group 2.34 (4.79) 3.94 (6.86) 1.67 (1.57-1.79) <0.0001 1.22 (1.09-1.36) 0.0004
No-cap group 3.30 (6.15) 4.66 (7.56) 1.37 (1.26-1.50) <0.0001 [Reference]
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; SD, standard deviation.
* Analyses were adjusted for sex; age; census-block group-level data concerning race, status below poverty line, residence; health status data (binary variables for
congestive heart failure, depression, diabetes, hypertension, and ischemic heart disease); and prospective risk score.
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claims data so we are limited in our ability to com-
ment on appropriateness of use. Our findings of
increased used over time, especially for memantine
(NamendaW), may be a result of the sample’s worsen-
ing cognition and progression to a more severe stage
of dementia rather than the impact of enhanced drug
coverage through Medicare Part D.
Medicare will need to rely on multiple strategies to
achieve its goal of increased access to evidence-
based care at the lowest cost. Studies have shown
that the introduction of Medicare Part D has had an
impact on the use of drugs with both strong and
weak evidence for effectiveness and that there are
differences in how sensitive demand is to changes in
out-of-pocket cost across drug classes. Our findings
show a significant increase in the use of antidementia
drugs over time among all beneficiaries with steeper
increases among those with improved coverage under
Medicare Part D.
Abbreviations
GEE: Generalized estimating equation; HCPCS: Healthcare common
procedure coding system; MANOVA: Multivariate analysis of variance.
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